Stem cell research targets ALS
The recent breakthroughs in stem cell research might nevertheless provide possibilities for neural implantation and cell replacement therapy for patients with ALS. The potential impact of these new approaches to neurodegenerative diseases has been emphasised by the many experiments using human foetal cell ...
Advancing ALS Research: Key Insights and Breakthroughs from the 2024 International Symposium on ALS/MND Read More Advancing ALS Research with Stem Cell Resources and Targeted Reagents: The Role of Target ALS in the Quest for Effective Treatments ...
(IND)-enabling preclinical studies in rodents and pigs, and findings from the first combined stem cell and ex vivo gene therapy trial for ALS. This 12-month phase 1/2a dose-escalation trial, which transplanted CNS10-NPC-GDNF unilaterally into the lumbar spinal cord of 18 patients with ALS,...
CORESTEM is a biotechnology company specializing in the research and development of personalized stem cell therapies for neurological and autoimmune diseases. Its lead product is NeuroNata-R (lenzumestrocel), the world’s first stem cell-based therapy for amyotrophic lateral sclerosis (ALS). ...
About 10 years ago, the Answer ALS consortium began to collect large numbers of patient samples, which could allow for larger-scale studies that might reveal some of the genetic drivers of the disease. From blood samples, researchers can create induced pluripotent stem cells and then induce them...
Stem cell treatment goes from lab to operating room | CNN.com(May 2010) Transplantation of spinal cord–derived neural stem cells for ALS Analysis of phase 1 and 2 trials Authors:Jonathan D. Glass, MD; Vicki S. Hertzberg, PhD; Nicholas M. Boulis, MD; Jonathan Riley, MD; Thais Federici...
Food and Drug Administration is expected for researchers and physicians at the University of Michigan to begin a second round of Phase 1 stem cell trials on patients with amyotrophic lateral sclerosis (ALS). ALS is a disease of the nerve cells in the brain and spinal cord that control ...
Largest ALS patient-based stem cell, biodata resource opens for research November 20, 2024 Columns by Dagmar Munn What I do when I’m feeling unmotivated in life with ALS November 20, 2024 News by Margarida Maia, PhD First-in-human trial of ALS therapy ASHA-624 expected in early 2025...
Researchers at Karolinska Institutet in Sweden have developed a stem cell-based model to study the resilience and vulnerability of neurons in the neurodegenerative disease ALS. The results are published in the journal Stem Cell Reports, and could aid in